Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Réa D[au]:

Search results

Items: 1 to 50 of 370

1.

6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial.

Earl HM, Hiller L, Vallier AL, Loi S, McAdam K, Hughes-Davies L, Harnett AN, Ah-See ML, Simcock R, Rea D, Raj S, Woodings P, Harries M, Howe D, Raynes K, Higgins HB, Wilcox M, Plummer C, Mansi J, Gounaris I, Mahler-Araujo B, Provenzano E, Chhabra A, Abraham JE, Caldas C, Hall PS, McCabe C, Hulme C, Miles D, Wardley AM, Cameron DA, Dunn JA; PERSEPHONE Steering Committee and Trial Investigators.

Lancet. 2019 Jun 6. pii: S0140-6736(19)30650-6. doi: 10.1016/S0140-6736(19)30650-6. [Epub ahead of print]

2.

The SMALL Trial: A Big Change for Small Breast Cancers.

Morgan J, Potter S, Sharma N, McIntosh SA; SMALL Trial Management Group, Coles CE, Dodwell D, Elder K, Gaunt C, Lyburn ID, McIntosh SA, Morgan J, Paramasivan S, Pinder S, Pirrie S, Potter S, Rea D, Roberts T, Sharma N, Stobart H, Taylor-Phillips S, Wallis M, Wilcox M.

Clin Oncol (R Coll Radiol). 2019 May 31. pii: S0936-6555(19)30200-6. doi: 10.1016/j.clon.2019.05.008. [Epub ahead of print] No abstract available.

PMID:
31160130
3.

Cardiotoxicity and pro-inflammatory effects of the immune checkpoint inhibitor Pembrolizumab associated to Trastuzumab.

Quagliariello V, Passariello M, Coppola C, Rea D, Barbieri A, Scherillo M, Monti MG, Iaffaioli RV, De Laurentiis M, Ascierto PA, Botti G, De Lorenzo C, Maurea N.

Int J Cardiol. 2019 May 17. pii: S0167-5273(18)37531-4. doi: 10.1016/j.ijcard.2019.05.028. [Epub ahead of print]

PMID:
31160077
4.

Effects of transdermal flunixin meglumine on experimentally induced lameness in adult dairy cattle.

Kleinhenz MD, Gorden PJ, Smith JS, Schleining JA, Kleinhenz KE, Juarez JR, Rea D, Coetzee JF.

J Dairy Sci. 2019 Jul;102(7):6418-6430. doi: 10.3168/jds.2018-15091. Epub 2019 Apr 25.

PMID:
31030917
5.

Naloxone Counteracts the Promoting Tumor Growth Effects Induced by Morphine in an Animal Model of Triple-negative Breast Cancer.

Bimonte S, Barbieri A, Cascella M, Rea D, Palma G, Luciano A, Forte CA, Cuomo A, Arra C.

In Vivo. 2019 May-Jun;33(3):821-825. doi: 10.21873/invivo.11545.

6.

Development of an anti-BAG3 humanized antibody for treatment of pancreatic cancer.

Basile A, De Marco M, Festa M, Falco A, Iorio V, Guerriero L, Eletto D, Rea D, Arra C, Lamolinara A, Ballerini P, Damiani V, Rosati A, Sala G, Turco MC, Marzullo L, De Laurenzi V.

Mol Oncol. 2019 Jun;13(6):1388-1399. doi: 10.1002/1878-0261.12492. Epub 2019 May 17.

7.

Valuing the health states associated with breast cancer screening programmes: A systematic review of economic measures.

Bromley HL, Petrie D, Mann GB, Nickson C, Rea D, Roberts TE.

Soc Sci Med. 2019 May;228:142-154. doi: 10.1016/j.socscimed.2019.03.028. Epub 2019 Mar 21. Review.

PMID:
30913528
8.

Dual Oncogenic/Anti-Oncogenic Role of PATZ1 in FRTL5 Rat Thyroid Cells Transformed by the Ha-RasV12 Oncogene.

Vitiello M, Palma G, Monaco M, Bello AM, Camorani S, Francesca P, Rea D, Barbieri A, Chiappetta G, Vita G, Cerchia L, Arra C, Fedele M.

Genes (Basel). 2019 Feb 9;10(2). pii: E127. doi: 10.3390/genes10020127.

9.

Poor prognosis of chromosome 7 clonal aberrations in Philadelphia-negative metaphases and relevance of potential underlying myelodysplastic features in chronic myeloid leukemia.

Bidet A, Dulucq S, Smol T, Marceau-Renaut A, Morisset S, Coiteux V, Noël-Walter MP, Nicolini FE, Tigaud I, Luquet I, Struski S, Gaillard B, Penther D, Tondeur S, Nadal N, Hermet E, Véronèse L, Réa D, Gervais C, Theisen O, Terré C, Cony-Makhoul P, Lefebvre C, Gaillard JB, Radford I, Vervaeke AL, Barin C, Chapiro E, Nguyen-Khac F, Etienne G, Preudhomme C, Mahon FX, Roche-Lestienne C; Groupe Francophone de Cytogénétique Hématologique (GFCH) and the French Intergroup of Chronic Myeloid Leukemia (Fi-LMC).

Haematologica. 2019 Jun;104(6):1150-1155. doi: 10.3324/haematol.2018.208801. Epub 2018 Dec 20.

10.

Binding of Distinct Substrate Conformations Enables Hydroxylation of Remote Sites in Thaxtomin D by Cytochrome P450 TxtC.

Alkhalaf LM, Barry SM, Rea D, Gallo A, Griffiths D, Lewandowski JR, Fulop V, Challis GL.

J Am Chem Soc. 2019 Jan 9;141(1):216-222. doi: 10.1021/jacs.8b08864. Epub 2018 Dec 19.

PMID:
30516965
11.

Eruptive melanocytic nevi associated with ponatinib.

Devred I, Arnault JP, Adas A, Rea D, Lombart F, Sevestre H, Trudel S, Lok C, Chaby G.

JAAD Case Rep. 2018 Nov 12;4(10):1052-1054. doi: 10.1016/j.jdcr.2018.07.010. eCollection 2018 Nov. No abstract available.

12.

Pathway-based subnetworks enable cross-disease biomarker discovery.

Haider S, Yao CQ, Sabine VS, Grzadkowski M, Stimper V, Starmans MHW, Wang J, Nguyen F, Moon NC, Lin X, Drake C, Crozier CA, Brookes CL, van de Velde CJH, Hasenburg A, Kieback DG, Markopoulos CJ, Dirix LY, Seynaeve C, Rea DW, Kasprzyk A, Lambin P, Lio' P, Bartlett JMS, Boutros PC.

Nat Commun. 2018 Nov 12;9(1):4746. doi: 10.1038/s41467-018-07021-3.

13.

Treatment-free remission with first- and second-generation tyrosine kinase inhibitors.

Cortes J, Rea D, Lipton JH.

Am J Hematol. 2019 Mar;94(3):346-357. doi: 10.1002/ajh.25342. Epub 2018 Nov 25. Review.

PMID:
30394563
14.

The presentation, management and outcome of inflammatory breast cancer cases in the UK: Data from a multi-centre retrospective review.

Copson E, Shaaban AM, Maishman T, Moseley PM, McKenzie H, Bradbury J, Borley A, Brzezinska M, Chan SYT, Ching J, Cutress RI, Danial I, Dall B, Kerin M, Lowery AJ, Macpherson IR, Romics L, Sawyer E, Sharmat N, Sircar T, Vidya R, Pan Y, Rea D, Jones L, Eccles DM, Berditchevski F.

Breast. 2018 Dec;42:133-141. doi: 10.1016/j.breast.2018.09.003. Epub 2018 Sep 15.

PMID:
30278369
15.

Ponatinib evaluation and safety in real-life chronic myelogenous leukemia patients failing more than two tyrosine kinase inhibitors: the PEARL observational study.

Heiblig M, Rea D, Chrétien ML, Charbonnier A, Rousselot P, Coiteux V, Escoffre-Barbe M, Dubruille V, Huguet F, Cayssials E, Hermet E, Guerci-Bresler A, Amé S, Sackmann-Sala L, Roy L, Sobh M, Morisset S, Etienne G, Nicolini FE.

Exp Hematol. 2018 Nov;67:41-48. doi: 10.1016/j.exphem.2018.08.006. Epub 2018 Sep 5.

PMID:
30195076
16.

Descent of the human larynx: An unrecognized factor in airway distress in babies with cleft palate?

de Blacam C, Duggan L, Rea D, Beddy P, Orr DJA.

Int J Pediatr Otorhinolaryngol. 2018 Oct;113:208-212. doi: 10.1016/j.ijporl.2018.07.052. Epub 2018 Jul 31. Review.

PMID:
30173987
17.

Incidence, outcomes, and risk factors of pleural effusion in patients receiving dasatinib therapy for Philadelphia chromosome-positive leukemia.

Hughes TP, Laneuville P, Rousselot P, Snyder DS, Rea D, Shah NP, Paar D, Abruzzese E, Hochhaus A, Lipton JH, Cortes JE.

Haematologica. 2019 Jan;104(1):93-101. doi: 10.3324/haematol.2018.188987. Epub 2018 Aug 9.

18.

[NK cells: a major role in the antitumoral immunomodulation in CML].

Toubert A, Turhan A, Guerci-Bresler A, Dulphy N, Réa D.

Med Sci (Paris). 2018 Jun-Jul;34(6-7):540-546. doi: 10.1051/medsci/20183406013. Epub 2018 Jul 31. Review. French.

PMID:
30067206
19.

Insulin resistance is an underlying mechanism of impaired glucose metabolism during nilotinib therapy.

Racil Z, Koritakova E, Sacha T, Klamova H, Belohlavkova P, Faber E, Rea D, Malaskova L, Prochazkova J, Zackova D, Voglova J, Wącław J, Cetkovsky P, Zak P, Mayer J.

Am J Hematol. 2018 Oct;93(10):E342-E345. doi: 10.1002/ajh.25232. Epub 2018 Aug 31. No abstract available.

PMID:
30054949
20.

Predictive Biomarkers for Endocrine Therapy: Retrospective Study in Tamoxifen and Exemestane Adjuvant Multinational (TEAM) Trial.

Roseweir AK, Bennett L, Dickson A, Cheng K, Quintayo MA, Bayani J, McMillan DC, Horgan PG, van de Velde CJH, Seynaeve C, Hasenburg A, Kieback DG, Markopoulos C, Dirix LY, Rea DW, Mallon EA, Bartlett JMS, Edwards J.

J Natl Cancer Inst. 2018 Jun 1;110(6):616-627. doi: 10.1093/jnci/djx255.

PMID:
29917140
21.

Impact of age on breast cancer mortality and competing causes of death at 10 years follow-up in the adjuvant TEAM trial.

Derks MGM, Bastiaannet E, van de Water W, de Glas NA, Seynaeve C, Putter H, Nortier JWR, Rea D, Hasenburg A, Markopoulos C, Dirix LY, Portielje JEA, van de Velde CJH, Liefers GJ.

Eur J Cancer. 2018 Aug;99:1-8. doi: 10.1016/j.ejca.2018.04.009. Epub 2018 Jun 6.

PMID:
29885375
22.

Maternal eating behaviour differs between ethnic groups: Considerations for research and practice.

Korani M, Rea DM, King PF, Brown AE.

Matern Child Nutr. 2018 Oct;14(4):e12630. doi: 10.1111/mcn.12630. Epub 2018 Jun 7.

PMID:
29877039
23.

SETBP1 induces transcription of a network of development genes by acting as an epigenetic hub.

Piazza R, Magistroni V, Redaelli S, Mauri M, Massimino L, Sessa A, Peronaci M, Lalowski M, Soliymani R, Mezzatesta C, Pirola A, Banfi F, Rubio A, Rea D, Stagno F, Usala E, Martino B, Campiotti L, Merli M, Passamonti F, Onida F, Morotti A, Pavesi F, Bregni M, Broccoli V, Baumann M, Gambacorti-Passerini C.

Nat Commun. 2018 Jun 6;9(1):2192. doi: 10.1038/s41467-018-04462-8.

24.

Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: Recommendations for clinical practice from the French Chronic Myeloid Leukemia Study Group.

Rea D, Ame S, Berger M, Cayuela JM, Charbonnier A, Coiteux V, Cony-Makhoul P, Dubruille V, Dulucq S, Etienne G, Legros L, Nicolini F, Roche-Lestienne C, Escoffre-Barbe M, Gardembas M, Guerci-Bresler A, Johnson-Ansah H, Rigal-Huguet F, Rousselot P, Mahon FX; French Chronic Myeloid Leukemia Study Group.

Cancer. 2018 Jul 15;124(14):2956-2963. doi: 10.1002/cncr.31411. Epub 2018 May 3.

PMID:
29723417
25.

International Consensus on the Clinical Management of Inflammatory Breast Cancer from the Morgan Welch Inflammatory Breast Cancer Research Program 10th Anniversary Conference.

Ueno NT, Espinosa Fernandez JR, Cristofanilli M, Overmoyer B, Rea D, Berdichevski F, El-Shinawi M, Bellon J, Le-Petross HT, Lucci A, Babiera G, DeSnyder SM, Teshome M, Chang E, Lim B, Krishnamurthy S, Stauder MC, Parmar S, Mohamed MM, Alexander A, Valero V, Woodward WA.

J Cancer. 2018 Apr 6;9(8):1437-1447. doi: 10.7150/jca.23969. eCollection 2018.

26.

Cardiotoxic effects of the novel approved anti-ErbB2 agents and reverse cardioprotective effects of ranolazine.

De Lorenzo C, Paciello R, Riccio G, Rea D, Barbieri A, Coppola C, Maurea N.

Onco Targets Ther. 2018 Apr 19;11:2241-2250. doi: 10.2147/OTT.S157294. eCollection 2018.

27.

Microbiota effects on cancer: from risks to therapies.

Rea D, Coppola G, Palma G, Barbieri A, Luciano A, Del Prete P, Rossetti S, Berretta M, Facchini G, Perdonà S, Turco MC, Arra C.

Oncotarget. 2018 Apr 3;9(25):17915-17927. doi: 10.18632/oncotarget.24681. eCollection 2018 Apr 3. Review.

28.

Significant differences in maternal child-feeding style between ethnic groups in the UK: the role of deprivation and parenting styles.

Korani M, Rea DM, King PF, Brown AE.

J Hum Nutr Diet. 2018 Oct;31(5):625-633. doi: 10.1111/jhn.12557. Epub 2018 Apr 3.

PMID:
29611252
29.

Generalized lymphatic anomaly successfully treated with long-term, low-dose sirolimus.

Dvorakova V, Rea D, O'Regan GM, Irvine AD.

Pediatr Dermatol. 2018 Jul;35(4):533-534. doi: 10.1111/pde.13494. Epub 2018 Mar 26.

PMID:
29582448
30.

Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial.

Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre PD, Paquette R, Chuah C, Nicolini FE, Apperley JF, Khoury HJ, Talpaz M, DeAngelo DJ, Abruzzese E, Rea D, Baccarani M, Müller MC, Gambacorti-Passerini C, Lustgarten S, Rivera VM, Haluska FG, Guilhot F, Deininger MW, Hochhaus A, Hughes TP, Shah NP, Kantarjian HM.

Blood. 2018 Jul 26;132(4):393-404. doi: 10.1182/blood-2016-09-739086. Epub 2018 Mar 22.

31.
32.

Tumor PIK3CA Genotype and Prognosis in Early-Stage Breast Cancer: A Pooled Analysis of Individual Patient Data.

Zardavas D, Te Marvelde L, Milne RL, Fumagalli D, Fountzilas G, Kotoula V, Razis E, Papaxoinis G, Joensuu H, Moynahan ME, Hennessy BT, Bieche I, Saal LH, Stal O, Iacopetta B, Jensen JD, O'Toole S, Lopez-Knowles E, Barbaraeschi M, Noguchi S, Azim HA Jr, Lerma E, Bachelot T, Wang Q, Perez-Tenorio G, Can de Velde CJH, Rea DW, Sabine V, Bartlett JMS, Sotiriou C, Michiels S, Loi S.

J Clin Oncol. 2018 Apr 1;36(10):981-990. doi: 10.1200/JCO.2017.74.8301. Epub 2018 Feb 22.

33.

Ranolazine Attenuates Trastuzumab-Induced Heart Dysfunction by Modulating ROS Production.

Riccio G, Antonucci S, Coppola C, D'Avino C, Piscopo G, Fiore D, Maurea C, Russo M, Rea D, Arra C, Condorelli G, Di Lisa F, Tocchetti CG, De Lorenzo C, Maurea N.

Front Physiol. 2018 Feb 6;9:38. doi: 10.3389/fphys.2018.00038. eCollection 2018.

34.

Pharmacokinetics of multiple doses of transdermal flunixin meglumine in adult Holstein dairy cows.

Kleinhenz MD, Gorden PJ, Smith JS, Schleining JA, Kleinhenz KE, Wulf LL, Sidhu PK, Rea D, Coetzee JF.

J Vet Pharmacol Ther. 2018 Jun;41(3):490-493. doi: 10.1111/jvp.12490. Epub 2018 Feb 20.

PMID:
29460288
35.

What is treatment free remission in chronic myeloid leukemia?

Rea D, Etienne G, Mahon FX.

Oncotarget. 2017 Dec 18;9(4):4279. doi: 10.18632/oncotarget.23398. eCollection 2018 Jan 12. No abstract available.

36.

Inhibition of tumor growth by cancer vaccine combined with metronomic chemotherapy and anti-PD-1 in a pre-clinical setting.

Petrizzo A, Mauriello A, Luciano A, Rea D, Barbieri A, Arra C, Maiolino P, Tornesello M, Gigantino V, Botti G, Ciliberto G, Buonaguro FM, Tagliamonte M, Buonaguro L.

Oncotarget. 2017 Dec 8;9(3):3576-3589. doi: 10.18632/oncotarget.23181. eCollection 2018 Jan 9.

37.

The effects of naloxone on human breast cancer progression: in vitro and in vivo studies on MDA.MB231 cells.

Bimonte S, Barbieri A, Cascella M, Rea D, Palma G, Del Vecchio V, Forte CA, Del Prato F, Arra C, Cuomo A.

Onco Targets Ther. 2018 Jan 3;11:185-191. doi: 10.2147/OTT.S145780. eCollection 2018.

38.

Inhibition of D-Ala:D-Ala ligase through a phosphorylated form of the antibiotic D-cycloserine.

Batson S, de Chiara C, Majce V, Lloyd AJ, Gobec S, Rea D, Fülöp V, Thoroughgood CW, Simmons KJ, Dowson CG, Fishwick CWG, de Carvalho LPS, Roper DI.

Nat Commun. 2017 Dec 5;8(1):1939. doi: 10.1038/s41467-017-02118-7.

39.

Ponatinib in chronic myeloid leukemia (CML): Consensus on patient treatment and management from a European expert panel.

Müller MC, Cervantes F, Hjorth-Hansen H, Janssen JJWM, Milojkovic D, Rea D, Rosti G.

Crit Rev Oncol Hematol. 2017 Dec;120:52-59. doi: 10.1016/j.critrevonc.2017.10.002. Epub 2017 Oct 8. Review.

40.

Confusion Over Differences in Registration and Randomization Criteria for the LORIS (Low-Risk DCIS) Trial.

Rea D, Francis A, Wallis M, Thomas J, Bartlett J, Bowden S, Dodwell D, Fallowfield L, Gaunt C, Hanby A, Jenkins V, Matthews L, Pinder S, Pirrie S, Reed M, Wilcox M, Roberts T, Kirwan C, Brookes C, Fairbrother P, Billingham L, Evans A, Young J.

Ann Surg Oncol. 2017 Dec;24(Suppl 3):566-567. doi: 10.1245/s10434-017-6174-y. Epub 2017 Nov 28. No abstract available.

PMID:
29185098
41.

HMGA2 cooperates with either p27kip1 deficiency or Cdk4R24C mutation in pituitary tumorigenesis.

Fedele M, Paciello O, De Biase D, Monaco M, Chiappetta G, Vitiello M, Barbieri A, Rea D, Luciano A, Papparella S, Arra C, Fusco A.

Cell Cycle. 2018;17(5):580-588. doi: 10.1080/15384101.2017.1403682. Epub 2018 Jan 30.

42.

How I manage relapse of chronic myeloid leukaemia after stopping tyrosine kinase inhibitor therapy.

Rea D, Mahon FX.

Br J Haematol. 2018 Jan;180(1):24-32. doi: 10.1111/bjh.14973. Epub 2017 Oct 19. Review.

PMID:
29048128
43.

Raising suspicion of maltreatment from burns: Derivation and validation of the BuRN-Tool.

Kemp AM, Hollén L, Emond AM, Nuttall D, Rea D, Maguire S.

Burns. 2018 Mar;44(2):335-343. doi: 10.1016/j.burns.2017.08.018. Epub 2017 Sep 14.

PMID:
28918905
44.

Sustained deep molecular responses in patients switched to nilotinib due to persistent BCR-ABL1 on imatinib: final ENESTcmr randomized trial results.

Hughes TP, Leber B, Cervantes F, Spector N, Pasquini R, Clementino NCD, Schwarer AP, Dorlhiac-Llacer PE, Mahon FX, Rea D, Guerci-Bresler A, Kamel-Reid S, Bendit I, Acharya S, Glynos T, Dalal D, Branford S, Lipton JH.

Leukemia. 2017 Nov;31(11):2529-2531. doi: 10.1038/leu.2017.247. Epub 2017 Aug 3. No abstract available.

45.

Crystal structure of Porphyromonas gingivalis dipeptidyl peptidase 4 and structure-activity relationships based on inhibitor profiling.

Rea D, Van Elzen R, De Winter H, Van Goethem S, Landuyt B, Luyten W, Schoofs L, Van Der Veken P, Augustyns K, De Meester I, Fülöp V, Lambeir AM.

Eur J Med Chem. 2017 Oct 20;139:482-491. doi: 10.1016/j.ejmech.2017.08.024. Epub 2017 Aug 10.

PMID:
28826083
46.

Mechanisms of resistance to the BCR-ABL1 allosteric inhibitor asciminib.

Qiang W, Antelope O, Zabriskie MS, Pomicter AD, Vellore NA, Szankasi P, Rea D, Cayuela JM, Kelley TW, Deininger MW, O'Hare T.

Leukemia. 2017 Dec;31(12):2844-2847. doi: 10.1038/leu.2017.264. Epub 2017 Aug 18. No abstract available.

PMID:
28819281
47.

Bone marrow mesenchymal stromal cell (MSC) gene profiling in chronic myeloid leukemia (CML) patients at diagnosis and in deep molecular response induced by tyrosine kinase inhibitors (TKIs).

Aggoune D, Sorel N, Bonnet ML, Goujon JM, Tarte K, Hérault O, Domenech J, Réa D, Legros L, Johnson-Ansa H, Rousselot P, Cayssials E, Guerci-Bresler A, Bennaceur-Griscelli A, Chomel JC, Turhan AG.

Leuk Res. 2017 Sep;60:94-102. doi: 10.1016/j.leukres.2017.07.007. Epub 2017 Jul 26.

PMID:
28772207
48.

Nonoperative Management for Invasive Breast Cancer After Neoadjuvant Systemic Therapy: Conceptual Basis and Fundamental International Feasibility Clinical Trials.

Kuerer HM, Vrancken Peeters MTFD, Rea DW, Basik M, De Los Santos J, Heil J.

Ann Surg Oncol. 2017 Oct;24(10):2855-2862. doi: 10.1245/s10434-017-5926-z. Epub 2017 Aug 1.

PMID:
28766204
49.

Second tyrosine kinase inhibitor discontinuation attempt in patients with chronic myeloid leukemia.

Legros L, Nicolini FE, Etienne G, Rousselot P, Rea D, Giraudier S, Guerci-Bresler A, Huguet F, Gardembas M, Escoffre M, Ianotto JC, Noël MP, Varet BR, Pagliardini T, Touitou I, Morisset S, Mahon FX; French Intergroup for Chronic Myeloid Leukemias.

Cancer. 2017 Nov 15;123(22):4403-4410. doi: 10.1002/cncr.30885. Epub 2017 Jul 25.

50.

Adjuvant tamoxifen and exemestane in women with postmenopausal early breast cancer (TEAM): 10-year follow-up of a multicentre, open-label, randomised, phase 3 trial.

Derks MGM, Blok EJ, Seynaeve C, Nortier JWR, Kranenbarg EM, Liefers GJ, Putter H, Kroep JR, Rea D, Hasenburg A, Markopoulos C, Paridaens R, Smeets JBE, Dirix LY, van de Velde CJH.

Lancet Oncol. 2017 Sep;18(9):1211-1220. doi: 10.1016/S1470-2045(17)30419-9. Epub 2017 Jul 18.

PMID:
28732650

Supplemental Content

Support Center